Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

No Clinical Trials Comparing The Safety Of Eliquis To Xarelto Done Yet

October 26, 2016 By Law Offices of Thomas J. Lamb, P.A.

In two medical study reports it seemed that Xarelto (rivaroxaban) was more likely to be involved in a serious bleeding event as an adverse reaction than was either Pradaxa (dabigatran) or Eliquis (apixaban).

Earlier this month the medical journal Chest published this article, “Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation”.

Also earlier this month, JAMA Internal Medicine published this article, “Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation.”

We get these insights from this October 7, 2016 article, “More NOAC Comparisons See Higher Bleeding Risk With Rivaroxaban: Is the ‘Writing on the Wall’?”:

The two new studies [published in the medical journal Chest and JAMA Internal Medicine] come close on the heels of an analysis by Danish researchers comparing [Pradaxa (dabigatran)], [Xarelto (rivaroxaban)], [Eliquis (apixaban)], and warfarin. In that analysis, [Pradaxa (dabigatran)] and [Eliquis (apixaban)] were associated with a significantly decreased risk of ICH compared with warfarin, but [Xarelto (rivaroxaban)] was not, although all three [non-vitamin K antagonist oral anticoagulants (NOACs)] were as effective as warfarin at reducing stroke in atrial fibrillation patients….

To date there are no randomized head-to-head trials comparing the new agents, but that is about to change. [Laila Stærk, MD (Herlev and Gentofte University Hospital, Denmark), who presented that data at the recent European Society of Cardiology Congress 2016,] told TCTMD that a new prospective, cluster randomized trial has just been announced in Denmark that will involve “almost all” hospitals in the country. Designed to run for 4 years, each hospital will just use one of the four approved NOACs ([Pradaxa (dabigatran)], [Xarelto (rivaroxaban)], [Savaysa (edoxaban)], and [Eliquis (apixaban)]) for the period of 1 year, then the next the next year, and so forth. At the end of the 4-year period, every participating hospital will have 1 year’s experience with each of the approved NOACs, with follow-up to continue for several years thereafter. Dubbed DEN-NOAC, the trial will be led by Casper Bang, MD (Rigshospitalet, Copenhagen, Denmark).

Of course, we will continue to monitor the still-emerging safety issues surrounding Eliquis, Savaysa, and Xarelto.

[Read this article in full at original source]

Free Eliquis Case Evaluation

Strictly Confidential, No Obligation


Free Savaysa Case Evaluation

Strictly Confidential, No Obligation


Free Xarelto Case Evaluation

Strictly Confidential, No Obligation


Filed Under: Unsafe Drugs Tagged With: bleeding risk, Eliquis, Hemorrhages, Prad, Savaysa, Uncontrollable Bleeding Events, Xarelto

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.